Patent classifications
C07D471/14
Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: ##STR00001##
or a pharmaceutically acceptable salt or prodrug thereof, wherein A.sub.1-A.sub.3, B.sub.1-B.sub.3, D.sub.1-D.sub.4 and R.sub.1-R.sub.2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
##STR00001##
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
##STR00001##
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
##STR00001##
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
##STR00001##
AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,
##STR00001##
Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compound of Formula (I).
AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,
##STR00001##
Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compound of Formula (I).
APOPTOSIS-INDUCING AGENTS
Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
GROUP OF TETRAHYDROINDOLOQUINAZOLINE COMPOUNDS AND USE THEREOF
The disclosure relates to an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound represented by general formula (I) and use thereof in the manufacture of (1) a medicament for treating a cardiovascular and cerebrovascular disease, (2) a formulation for increasing expression of AMPK, ABCA1 and SR-BI, (3) a formulation for activating nuclear receptors (NRs), and inhibiting activity of NLRP3, IL-1β, NF-κB and MAPKs, (4) a formulation for promoting cellular cholesterol efflux; or (5) a medicament for anti-inflammation.
##STR00001##
GROUP OF TETRAHYDROINDOLOQUINAZOLINE COMPOUNDS AND USE THEREOF
The disclosure relates to an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound represented by general formula (I) and use thereof in the manufacture of (1) a medicament for treating a cardiovascular and cerebrovascular disease, (2) a formulation for increasing expression of AMPK, ABCA1 and SR-BI, (3) a formulation for activating nuclear receptors (NRs), and inhibiting activity of NLRP3, IL-1β, NF-κB and MAPKs, (4) a formulation for promoting cellular cholesterol efflux; or (5) a medicament for anti-inflammation.
##STR00001##